NCT01025206

A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma

A Phase I Dose-Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of BI 505, a Human Anti-Intercellular Adhesion Molecule 1 Monoclonal Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 35 (actual)
• Sponsor: BioInvent International AB · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a first in human study which will assess the safety and tolerability of a monoclonal antibody against ICAM-1 in patients with Multiple Myeloma. The tumour response rate will also be measured.

Conditions

• Multiple Myeloma

Interventions

Type	Name	Description
BIOLOGICAL	BI-505	Anti-ICAM-1 monoclonal antibody given as a i.v infusion every second week for four weeks,

Timeline

• Start date: 2009-12-01
• Primary completion: 2013-02-01
• Completion: 2013-02-01
• First posted: 2009-12-03
• Last updated: 2013-03-15

Locations

7 sites across 4 countries: United States, Belgium, Denmark, Sweden